



July 14, 2026

In late May, the Office of Management and Budget (OMB) released a [proposed rule](#) to revise federal guidelines for federal financial assistance, including research grants. While the stated goal of the proposed rule is to improve transparency, accountability, and oversight for federal grantmaking, it contains many alarming provisions that would compromise funding decisions and potentially impede scientific progress. As the leading private funder of lung cancer research and an organization dedicated to transforming the experience of every person impacted by lung cancer, LUNGEvity is committed to advocating for policies that promote scientific rigor, funding stability, collaboration, and patient access to the best available care.

In comments submitted to OMB, we highlighted concerns that the proposed rule would:

1. Insert political appointees into the scientific review of individual grant applications;
2. Expand agencies' authority to terminate active, multi-year research awards without any finding of fraud or noncompliance;
3. Restrict federally funded researchers from attending conferences, publishing in peer-reviewed journals, or otherwise communicating their findings to the public; and
4. Impede the international scientific collaboration on which much of modern lung cancer research depends.

For more information, please view our full comment letter [here](#).